|
|
Taiwan Academic Institutional Repository >
Browse by Title
|
Showing items 551401-551410 of 2348487 (234849 Page(s) Totally)
<< < 55136 55137 55138 55139 55140 55141 55142 55143 55144 55145 > >>
View [10|25|50] records per page
| 國立臺灣大學 |
2004 |
Lipoprotein-X Reduces Ldl Atherogenicity in Primary Biliary Cirrhosis by Preventing Ldl Oxidation
|
張博淵; 呂紹俊; 蘇大成; 周三芳; 廖朝崧; 李源德; CHANG, PO-YUAN; LU, SHAO-CHUN; SU, TA-CHEN; CHOU, SAN-FANG; LIAU, CHIAU-SUONG; LEE, YUAN-THE |
| 臺大學術典藏 |
2018-09-10T04:49:21Z |
Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation
|
Chang, P.-Y. and Lu, S.-C. and Su, T.-C. and Chou, S.-F. and Huang, W.-H. and Morrisett, J.D. and Chen, C.-H. and Liau, C.-S. and Lee, Y.-T.; TA-CHEN SU |
| 臺大學術典藏 |
2020-02-06T08:11:33Z |
Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation
|
Chang P.-Y.; SHAO-CHUN LU; Su T.-C.; Chou S.-F.; Huang W.-H.; Morrisett J.D.; Chen C.-H.; Liau C.-S.; Lee Y.-T.; Chang P.-Y.;Shao-Chun Lu;Su T.-C.;Chou S.-F.;Huang W.-H.;Morrisett J.D.;Chen C.-H.;Liau C.-S.;Lee Y.-T. |
| 臺大學術典藏 |
2020-09-28T02:48:05Z |
Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation
|
Chang P.-Y.;Lu S.-C.;Ta-Chen Su;Chou S.-F.;Huang W.-H.;Morrisett J.D.;Chen C.-H.;Liau C.-S.;Lee Y.-T.; Chang P.-Y.; Lu S.-C.; TA-CHEN SU; Chou S.-F.; Huang W.-H.; Morrisett J.D.; Chen C.-H.; Liau C.-S.; Lee Y.-T. |
| 臺大學術典藏 |
2004 |
Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation
|
Morrisett J.D.; Huang W.-H.; Chou S.-F.; Su T.-C.; Lu S.-C.; PO-YUAN CHANG; Chen C.-H.; Liau C.-S.; Lee Y.-T. |
| 高雄醫學大學 |
2004 |
Liposomal doxorubicin 治療引起的肢端紅斑症
|
薛強文;沈育如;陳國熏 |
| 義守大學 |
2017-04 |
Liposomal Encapsulation for Systemic Delivery of Propranolol via Transdermal Iontophoresis Improves Bone Microarchitecture in Ovariectomized Rats
|
Benjamin Teong;Shyh Ming Kuo;Wei-Hsin Tsai;Mei-Ling Ho;Chung-Hwan Chen;Han Hsiang Huang |
| 國家衛生研究院 |
2018-11 |
Liposomal irinotecan (nal-IRI) plus 5-FU/LV in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) progressing on gemcitabine-based treatment: Further subgroup analyses of the pivotal NAPOLI-1 study
|
Chen, LT;Mercade, TM;Lee, KH;Lakatos, G;Wang-Gillam, A;Mirakhur, B;de Jong, F |
| 國家衛生研究院 |
2020-01 |
Liposomal irinotecan + 5-FU/LV in metastatic pancreatic cancer: Subgroup analyses of patient, tumor, and previous treatment characteristics in the pivotal NAPOLI-1 trial
|
Macarulla Mercade, T;Chen, LT;Li, CP;Siveke, JT;Cunningham, D;Bodoky, G;Blanc, JF;Lee, KH;Dean, A;Belanger, B;Wang-Gillam, A |
| 國立成功大學 |
2020 |
Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial
|
MacArulla, Mercad� T.;Chen, L.-T.;Li, C.-P.;Siveke, J.T.;Cunningham, D.;Bodoky, G.;Blanc, J.-F.;Lee, K.-H.;Dean, A.;Belanger, Belanger B.;Wang-Gillam, A. |
Showing items 551401-551410 of 2348487 (234849 Page(s) Totally)
<< < 55136 55137 55138 55139 55140 55141 55142 55143 55144 55145 > >>
View [10|25|50] records per page
|
